Growth hormone peptides reliably do one thing and the marketed things barely at all: they nudge your own pituitary to release more growth hormone, which shows up on a lab report as higher IGF-1. In tesamorelin’s pivotal 26-week trial, IGF-1 climbed about 81% while deep visceral belly fat fell about 15% against placebo (Trial). That is close to the ceiling of what is actually proven. The promised payoff, more muscle, deeper sleep, slowed aging, extra years, is mostly untested, and the longevity evidence leans the other way, because higher IGF-1 is linked to more cancer, not less.
What Growth Hormone Peptides Are
Growth hormone peptides are short amino-acid chains that raise your body’s own growth hormone rather than replacing it. They split into two families with different triggers. GHRH analogs copy your natural growth-hormone-releasing hormone; this group includes sermorelin, CJC-1295, and tesamorelin. Growth hormone secretagogues, also called ghrelin mimetics, act through the hunger-hormone receptor instead; the best-studied are ipamorelin and the oral compound MK-677 (ibutamoren).
Both families share a selling point. Instead of injecting synthetic growth hormone, they coax the pituitary to release its own in pulses, which marketers describe as more physiological because it preserves the body’s natural feedback loops. In practice, most of these peptides reach users not through a pharmacy but through subscription telehealth clinics and online vendors that ship injectable powder to reconstitute at home, which is exactly why the purity question below carries so much weight. The pharmacology backs the first half of the pitch. A single dose of CJC-1295 raised mean growth hormone 2- to 10-fold for at least six days and lifted IGF-1 (insulin-like growth factor 1, the downstream messenger that carries most of growth hormone’s effects) 1.5- to 3-fold for up to eleven days in healthy adults (Trial). Raising the number is not the hard part. Proving that the number does anything you actually want is.
Tesamorelin, The Proven One
Only one of these peptides has cleared a regulator. Tesamorelin (brand name Egrifta) was approved by the FDA in November 2010 to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy, the first drug cleared for that condition (FDA approval). Everything else in the category is either withdrawn, unapproved, or sold for uses no agency has signed off on.
The pivotal data are genuinely solid. In a 26-week randomized trial of 412 HIV patients with abdominal fat accumulation, 2 mg of daily tesamorelin cut visceral fat by 15.2% while it rose 5% on placebo, and IGF-1 climbed 81% (Trial). A pooled analysis of the two Phase III trials found a net visceral-fat reduction of roughly 15% over 26 weeks, alongside IGF-1 increases of about 106 to 109 ng/mL (Review). A 2026 meta-analysis of five randomized trials, again in HIV-associated lipodystrophy, confirmed the pattern: visceral fat down, liver fat down about 4%, lean body mass up about 1.4 kg, with “no serious side effects or perturbation of glucose” (Meta-analysis). The side effects that did show up, joint aches, muscle aches, tingling, and injection-site redness, were all non-serious (Meta-analysis).
The metabolic record is close to neutral, with one honest caveat. A separate randomized trial found tesamorelin cut liver fat by 2.9% and visceral fat by about 42 cm2 while leaving fasting glucose, insulin, and lipids essentially unchanged, but HbA1c, a three-month blood-sugar average, rose a small yet statistically significant 0.19% (Trial). This is the strongest evidence any growth hormone peptide has, and it is worth being clear about what it shows: a specific benefit, in a specific patient group, for a specific problem. It is not a demonstration that healthy adults get leaner, stronger, or younger. It is the ceiling, not the floor.
Do They Build Muscle?
Here is where the marketing and the evidence part ways. Raising IGF-1 to youthful levels turns out not to be the same thing as getting stronger.
The cleanest test used MK-677. In a two-year randomized trial, 65 healthy adults aged 60 to 81 took the oral secretagogue daily. Growth hormone rose 1.8-fold and IGF-1 rose 1.5-fold, back into the range of a healthy young adult, and fat-free mass increased about 1.1 kg versus a slight loss on placebo. Then comes the sentence that deflates the whole pitch: “Increased fat-free mass did not result in changes in strength or function” (Trial). More lean mass on the scale, no measurable gain in what that mass is supposed to do. That gap matters because fat-free mass bundles water and connective tissue in with muscle, so a rising number does not prove the muscle pulls any harder. The researchers checked strength and physical function directly, and quality of life alongside, and none of them moved (Trial). Some of the added weight is likely water, since raising growth hormone promotes fluid retention rather than pure contractile muscle.
For the two peptides sold hardest to gym-goers, the human muscle data barely exist. CJC-1295’s only randomized human trials measured growth hormone and IGF-1 and nothing else, with no body-composition or strength endpoints at all (Trial). Ipamorelin has never been tested in a human trial for muscle or body composition; its one completed randomized trial treated postoperative bowel recovery and missed even that primary endpoint (Trial). So the honest status is this: the pituitary responds, the lab values move, and whether any of it builds usable muscle in a healthy person is simply unstudied.
The IGF-1 Longevity Paradox
Here is the uncomfortable part. The whole anti-aging premise is that restoring youthful IGF-1 should slow aging. The longevity literature points the opposite way.
Start with the strongest human evidence. People with Laron syndrome, a genetic inability to respond to growth hormone, keep IGF-1 very low for life. Over 22 years, an Ecuadorian cohort of 99 such individuals had just one non-lethal cancer and zero cases of diabetes, while their unaffected relatives died of cancer roughly 20% of the time and developed diabetes at normal rates; the affected group also had markedly lower fasting insulin and better insulin sensitivity (Study). Low growth-hormone signaling, in other words, tracked with dramatic protection.
The pattern holds in ordinary aging. Among 184 people in their nineties, women with below-median IGF-1 lived significantly longer, and among those with a prior cancer history, low-IGF-1 individuals survived a median of 49.6 months versus 20.7 (Study). In 858 nonagenarian siblings, the lowest quartile of IGF-1 signaling had a 27% lower death rate than the highest (Study). Lower signal, longer life. The direction is consistent enough that reduced growth-hormone and IGF-1 signaling has become one of the more studied levers in longevity research, which is precisely what makes a product designed to push that signal upward worth a second look.
Now the cancer link, which is the mechanism people worry about. In 394,388 UK Biobank participants, each 5 nmol/L step up in IGF-1 was associated with an 11% higher risk of breast cancer (Study). In an individual-participant meta-analysis pooling 19 studies, men in the highest fifth of IGF-1 had about a 29% higher risk of prostate cancer than the lowest (Meta-analysis). None of this proves a secretagogue causes cancer, and these are associations rather than verdicts; the people in these cohorts were not taking peptides, and low lifelong IGF-1 is not the same as briefly nudging it up in midlife. But the direction is consistent across independent datasets, and it is exactly the direction these peptides push. Deliberately raising IGF-1 for its own sake may be nudging a lever the longevity data suggest you would want lower, not higher, which is the single strongest reason to be cautious about the anti-aging pitch.
Safety, Sourcing and Purity
The regulatory map here is messier than the marketing implies. Only tesamorelin is approved. Sermorelin was approved once, as Geref, then discontinued in 2008; importantly, the FDA formally determined that it was not withdrawn for reasons of safety or effectiveness, but for reasons unrelated to either (FDA determination). That leaves the two peptides the gray market leans on hardest, CJC-1295 and ipamorelin, with no approval at all. Both are unapproved drugs that are not components of any approved product, and in 2023 the FDA placed them in interim 503A Category 2, judging them too risky or too poorly characterized for pharmacy compounding (Investigation).
The metabolic signals deserve attention because they run against the anti-aging story. In that same two-year MK-677 trial, the secretagogue significantly worsened blood-sugar control: fasting glucose rose about 5 mg/dL, HbA1c rose 0.2%, insulin sensitivity fell, and four participants needed a dose reduction for elevated glucose (Trial). Raising growth hormone tends to raise insulin resistance, which is the opposite of what someone chasing healthspan should want. Even approved tesamorelin nudged HbA1c upward (Trial).
The cardiac signal is more pointed. A phase II trial of the secretagogue MK-0677 in elderly hip-fracture patients was stopped early over a congestive heart failure safety signal, which appeared in roughly 6.5% of treated patients versus 1.7% on placebo (Trial). The fluid retention that flatters body composition on paper is the same mechanism implicated in that heart-failure signal, a reminder that “raises growth hormone” is not automatically benign.
Then there is what is actually in the vial. Because CJC-1295 and ipamorelin are compounded or sold outside the approval system, purity, dose accuracy, and sterility are not guaranteed, and the FDA’s own reviewers flagged these peptides as lacking the safety data needed to dispense them (Investigation). You may be injecting less, more, or something other than what the label claims. That is not a fringe concern; it is the baseline condition of this market, and it is the reason anyone weighing these compounds should involve a clinician rather than a vendor’s dosing blog.
Frequently Asked Questions
Are growth hormone peptides FDA-approved?
Mostly no. Only tesamorelin (Egrifta) is FDA-approved, and only to reduce visceral abdominal fat in people with HIV-associated lipodystrophy, not for anti-aging or muscle building (FDA approval). Sermorelin was approved years ago but discontinued in 2008 for reasons unrelated to safety or effectiveness (FDA determination). The popular gym peptides CJC-1295 and ipamorelin are not approved at all and were flagged by the FDA as too poorly characterized for compounding (Investigation).
Do CJC-1295 and ipamorelin build muscle?
There is no good human evidence that they do. CJC-1295’s only randomized human trials measured growth hormone and IGF-1 and never looked at muscle or body composition (Trial), and ipamorelin has never been tested in people for muscle at all; its one completed trial was for postoperative bowel recovery (Trial). The closest read-across, a two-year trial of a related secretagogue, added lean mass but produced no gain in strength or physical function (Trial).
Do growth hormone peptides cause cancer?
No study shows that they cause cancer, but the underlying biology is a legitimate concern. Higher circulating IGF-1, which these peptides raise, is associated with a higher risk of breast cancer (Study) and prostate cancer (Meta-analysis) in large studies, while people with naturally low IGF-1 develop far less cancer (Study). These are associations rather than proof, but they point in a worrying direction for a product whose entire purpose is to raise IGF-1.
Are growth hormone peptides safe?
Only tesamorelin has a real safety record, and even it modestly raised HbA1c (Trial). The oral secretagogue MK-677 worsened blood-sugar control in a two-year trial (Trial), and a related compound’s trial was halted early for a heart-failure signal (Trial). For the unapproved peptides, purity and dosing are not guaranteed (Investigation), so “safe” is not a claim the current evidence supports.
Key Takeaways
- They reliably raise IGF-1. This is the one thing growth hormone peptides do dependably: tesamorelin lifted IGF-1 about 81% in its pivotal trial (Trial).
- Tesamorelin is the only proven one. A meta-analysis of five randomized trials confirms it cuts visceral and liver fat and adds lean mass without disturbing glucose, but only in HIV-associated lipodystrophy (Meta-analysis).
- Restoring IGF-1 did not restore strength. MK-677 raised IGF-1 to youthful levels and added lean mass but produced no gain in strength or function (Trial).
- The IGF-1 tradeoff is real. Higher IGF-1 is linked to more breast (Study) and prostate cancer (Meta-analysis), while naturally low IGF-1 tracks with less cancer and longer life (Study).
- Most versions are gray-market. CJC-1295 and ipamorelin are unapproved and were judged too risky for compounding, with no purity guarantee (Investigation).
- The metabolic direction is wrong. Growth-hormone secretagogues worsened blood-sugar control in a controlled trial (Trial).
Signal, Hype, and Smart Caution
Here is the clean split. The signal is real: these peptides raise your own growth hormone and IGF-1, and tesamorelin turns that into a measurable, approved benefit for one specific medical problem. The hype is the leap from “the lab number moved” to “you will be more muscular, better rested, and biologically younger,” a leap the human evidence has not made. When researchers raised IGF-1 to youthful levels, strength did not follow, and the longevity data quietly suggest the youthful number may not even be the one you want.
That does not make these compounds worthless, or make everyone chasing them foolish. It makes them interesting pharmacology with an unproven anti-aging story and a real tradeoff attached, sold largely through an unregulated market where you cannot be sure what is in the syringe. If a clinician is treating a condition tesamorelin is approved for, that is a very different conversation from buying gray-market vials to turn back the clock.
So treat the numbers with respect and the promises with patience. Ask what outcome actually improved, not just which hormone rose, and take any decision about peptides to a clinician who can weigh your own risks. The pharmacology is real; the anti-aging payoff is still a promise, not a result, and that distinction is the most useful thing you can carry out of here.
This article is for educational purposes and is not medical advice. Talk to a qualified clinician before changing your health regimen.
Leave a comment